New drug aims to stop chemo side effect in nose and throat cancer

NCT ID NCT07252375

Not yet recruiting Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug hetrombopag can prevent severe low platelet counts caused by chemotherapy in people with nasopharyngeal carcinoma. About 35 patients who already had low platelets during a previous chemo cycle will take hetrombopag tablets daily during their next two cycles. The goal is to see if this reduces the risk of dangerous bleeding and helps patients stay on schedule with their cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hetrombopag olamine tablets
What this could lead to: If it works, this could help nasopharyngeal carcinoma patients avoid dangerous drops in platelets during chemotherapy, allowing them to complete their treatment as planned.
What could go wrong: This is a small, early-phase trial with only 35 participants and no comparison group, so results may not apply broadly. The drug may not prevent low platelets effectively or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTIT-CHEMOTHERAPY INDUCED THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma chemotherapy-induced toxicity prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTIT-CHEMOTHERAPY INDUCED THROMBOCYTOPENIA NASOPHARYNGEAL CARCINOMA (NPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.